Funding This work was supported by the Heart and Stroke Foundation of Canada (HSFC Grant in Aid Award #G-14-0005706 and HSFC-Ontario Personnel Award Phase I Career #7500 to AMJ), South Eastern Ontario Academic Medical Organization (SEAMO Clinician Award to AMJ), and Queens University (Department of Medicine Research Award to AMJ)
At home, they reported their drinking in a structured interview that walks back through the calendar
Through last year, there were rumors that she was considering a comeback
Semaglutide (Ozempic/Wegovy) Timeline Phase 3 trials began: 2015 (SUSTAIN program for diabetes) FDA approval (Ozempic for diabetes): December 2017 Commercial availability: Early 2018 Wegovy (obesity indication) Phase 3: 2018-2020 (STEP program) Wegovy FDA approval: June 2021 Wegovy commercial launch: September 2021, immediately went into shortage due to overwhelming demand Stable widespread availability: Mid-2023 (after Novo Nordisk scaled up manufacturing) Total time from Phase 3 start to stable availability: About 8 years for diabetes indication, 5 years for obesity indication (but with significant supply constraints)
BPC-157 may accelerate this remodeling process, but I still recommend completing full protocols and progressing through proper rehabilitation before resuming high-risk activities
So whats the real difference between Tirzepatide vs Semaglutide
